MX2019011986A - Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas. - Google Patents
Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas.Info
- Publication number
- MX2019011986A MX2019011986A MX2019011986A MX2019011986A MX2019011986A MX 2019011986 A MX2019011986 A MX 2019011986A MX 2019011986 A MX2019011986 A MX 2019011986A MX 2019011986 A MX2019011986 A MX 2019011986A MX 2019011986 A MX2019011986 A MX 2019011986A
- Authority
- MX
- Mexico
- Prior art keywords
- human igm
- constant regions
- dependent
- cytolysis
- modulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Prostheses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483087P | 2017-04-07 | 2017-04-07 | |
| PCT/US2018/026474 WO2018187702A2 (en) | 2017-04-07 | 2018-04-06 | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019011986A true MX2019011986A (es) | 2019-11-07 |
Family
ID=63713537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019011986A MX2019011986A (es) | 2017-04-07 | 2018-04-06 | Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11401337B2 (enExample) |
| EP (1) | EP3607091A4 (enExample) |
| JP (3) | JP2020512820A (enExample) |
| KR (1) | KR102696143B1 (enExample) |
| CN (1) | CN110536900B (enExample) |
| AU (1) | AU2018248336B2 (enExample) |
| CA (1) | CA3055790A1 (enExample) |
| IL (1) | IL268901B2 (enExample) |
| MX (1) | MX2019011986A (enExample) |
| SG (1) | SG11201908051RA (enExample) |
| WO (1) | WO2018187702A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3105250T3 (da) | 2014-02-10 | 2020-09-28 | Igm Biosciences Inc | Multispecifikke iga-bindingsmolekyler |
| HUE042829T2 (hu) | 2014-04-03 | 2019-07-29 | Igm Biosciences Inc | Módosított J-lánc |
| CA2972990A1 (en) | 2015-01-20 | 2016-07-28 | Beatrice Tien-Yi WANG | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
| PL3265575T3 (pl) | 2015-03-04 | 2021-11-29 | Igm Biosciences, Inc. | Cząsteczki wiążące CD20 i ich zastosowania |
| CA2980751A1 (en) | 2015-03-25 | 2016-09-29 | Stephen F. Carroll | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| JP6811723B2 (ja) | 2015-04-17 | 2021-01-13 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法 |
| AU2016329197B2 (en) | 2015-09-30 | 2021-01-21 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
| CN108463472A (zh) | 2015-09-30 | 2018-08-28 | Igm生物科学有限公司 | 具有修饰的j-链的结合分子 |
| SG11201809336QA (en) | 2016-05-09 | 2018-11-29 | Igm Biosciences Inc | Anti-pd-l1 antibodies |
| MX2019011986A (es) * | 2017-04-07 | 2019-11-07 | Igm Biosciences Inc | Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas. |
| CA3091144A1 (en) | 2018-03-01 | 2019-09-06 | Igm Biosciences, Inc. | Igm fc and j-chain mutations that affect igm serum half-life |
| AU2019368289A1 (en) * | 2018-10-23 | 2021-04-29 | Igm Biosciences, Inc. | Multivalent IgM- and IgA-Fc-based binding molecules |
| BR112022002780A2 (pt) * | 2019-08-15 | 2022-05-10 | Igm Biosciences Inc | Moléculas de ligação multiméricas imunoestimulatórias |
| EP4031252A4 (en) * | 2019-09-19 | 2023-09-13 | IGM Biosciences, Inc. | Multimeric antibodies with enhanced selectivity for cells with high target density |
| CA3173414A1 (en) | 2020-04-22 | 2021-10-28 | Bruce Keyt | Pd-1 agonist multimeric binding molecules |
| GEAP202416592A (en) * | 2022-02-03 | 2024-11-11 | Igm Biosciences Inc | Anti-cd38 binding molecules and uses thereof |
| WO2023196995A1 (en) | 2022-04-07 | 2023-10-12 | Repertoire Immune Medicines, Inc. | T cell receptor multimers and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256771A (en) | 1990-04-03 | 1993-10-26 | Miles Inc. | Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation |
| WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| US20050014932A1 (en) | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
| US20150071948A1 (en) * | 2003-09-26 | 2015-03-12 | Gregory Alan Lazar | Novel immunoglobulin variants |
| TW200540186A (en) * | 2003-12-25 | 2005-12-16 | Kirin Brewery | Mutants of anti-CD40 antibody |
| AU2005304973A1 (en) | 2004-11-05 | 2006-05-18 | Palingen, Inc. | Antibody induced cell membrane wounding |
| WO2011056997A1 (en) | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| EP2760891B1 (en) | 2011-09-26 | 2018-11-07 | JN Biosciences LLC | Hybrid constant regions |
| KR102102111B1 (ko) | 2012-02-08 | 2020-04-20 | 아이쥐엠 바이오사이언스 인코포레이티드 | Ｃｄｉｍ 결합 단백질 및 이의 용도 |
| CN105722855B (zh) | 2013-09-05 | 2021-04-23 | Igm生物科学股份有限公司 | 恒定链经修饰的双特异性五价和六价Ig-M抗体 |
| US9416496B2 (en) * | 2013-10-16 | 2016-08-16 | Georgia-Pacific Consumer Products Lp | Method for reducing the bulk and increasing the density of a tissue product |
| DK3105250T3 (da) | 2014-02-10 | 2020-09-28 | Igm Biosciences Inc | Multispecifikke iga-bindingsmolekyler |
| JP6512214B2 (ja) | 2014-02-25 | 2019-05-15 | 富士レビオ株式会社 | 改変単量体ＩｇＭ |
| HUE042829T2 (hu) | 2014-04-03 | 2019-07-29 | Igm Biosciences Inc | Módosított J-lánc |
| CA2972990A1 (en) | 2015-01-20 | 2016-07-28 | Beatrice Tien-Yi WANG | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
| PL3265575T3 (pl) | 2015-03-04 | 2021-11-29 | Igm Biosciences, Inc. | Cząsteczki wiążące CD20 i ich zastosowania |
| CA2980751A1 (en) | 2015-03-25 | 2016-09-29 | Stephen F. Carroll | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| JP6811723B2 (ja) | 2015-04-17 | 2021-01-13 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法 |
| BR112018005573A2 (pt) | 2015-09-21 | 2019-01-22 | Aptevo Research And Development Llc | ?polipeptídeos de ligação a cd3? |
| AU2016329197B2 (en) | 2015-09-30 | 2021-01-21 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
| CN108463472A (zh) | 2015-09-30 | 2018-08-28 | Igm生物科学有限公司 | 具有修饰的j-链的结合分子 |
| CN105441455B (zh) * | 2015-10-21 | 2020-08-28 | 重庆金迈博生物科技有限公司 | 一种嵌合核酸分子及其在人源化抗体制备中的应用 |
| SG11201809336QA (en) | 2016-05-09 | 2018-11-29 | Igm Biosciences Inc | Anti-pd-l1 antibodies |
| EP3496536A4 (en) | 2016-07-20 | 2020-02-12 | IGM Biosciences, Inc. | MULTIMERE CD40-BINDING MOLECULES AND USES THEREOF |
| US20190330374A1 (en) | 2016-07-20 | 2019-10-31 | Igm Biosciences, Inc. | Multimeric ox40 binding molecules and uses thereof |
| EP3487298A4 (en) | 2016-07-20 | 2020-03-11 | IGM Biosciences, Inc. | MULTIMERE CD137 / 4-1BB-BINDING MOLECULES AND USES THEREOF |
| US20190330360A1 (en) | 2016-07-20 | 2019-10-31 | Igm Biosciences, Inc. | Multimeric gitr binding molecules and uses thereof |
| MX2019011986A (es) * | 2017-04-07 | 2019-11-07 | Igm Biosciences Inc | Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas. |
| US20200392239A1 (en) | 2018-02-26 | 2020-12-17 | Igm Biosciences, Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
| CA3091144A1 (en) | 2018-03-01 | 2019-09-06 | Igm Biosciences, Inc. | Igm fc and j-chain mutations that affect igm serum half-life |
| AU2019368289A1 (en) | 2018-10-23 | 2021-04-29 | Igm Biosciences, Inc. | Multivalent IgM- and IgA-Fc-based binding molecules |
-
2018
- 2018-04-06 MX MX2019011986A patent/MX2019011986A/es unknown
- 2018-04-06 AU AU2018248336A patent/AU2018248336B2/en active Active
- 2018-04-06 KR KR1020197030684A patent/KR102696143B1/ko active Active
- 2018-04-06 CA CA3055790A patent/CA3055790A1/en active Pending
- 2018-04-06 US US16/500,292 patent/US11401337B2/en active Active
- 2018-04-06 JP JP2019554816A patent/JP2020512820A/ja not_active Withdrawn
- 2018-04-06 WO PCT/US2018/026474 patent/WO2018187702A2/en not_active Ceased
- 2018-04-06 CN CN201880022469.1A patent/CN110536900B/zh active Active
- 2018-04-06 SG SG11201908051RA patent/SG11201908051RA/en unknown
- 2018-04-06 EP EP18781914.9A patent/EP3607091A4/en active Pending
-
2019
- 2019-08-25 IL IL268901A patent/IL268901B2/en unknown
-
2022
- 2022-06-10 US US17/806,339 patent/US20220340676A1/en not_active Abandoned
-
2023
- 2023-04-07 JP JP2023062508A patent/JP2023085503A/ja active Pending
-
2024
- 2024-10-07 JP JP2024175523A patent/JP2024177479A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110536900B (zh) | 2024-06-11 |
| US20210147567A1 (en) | 2021-05-20 |
| JP2023085503A (ja) | 2023-06-20 |
| IL268901B2 (en) | 2025-11-01 |
| KR102696143B1 (ko) | 2024-08-21 |
| CA3055790A1 (en) | 2018-10-11 |
| AU2018248336A1 (en) | 2019-09-26 |
| IL268901B1 (en) | 2025-07-01 |
| JP2024177479A (ja) | 2024-12-19 |
| EP3607091A4 (en) | 2021-01-20 |
| CN110536900A (zh) | 2019-12-03 |
| IL268901A (en) | 2019-10-31 |
| SG11201908051RA (en) | 2019-09-27 |
| WO2018187702A2 (en) | 2018-10-11 |
| AU2018248336B2 (en) | 2024-10-03 |
| US11401337B2 (en) | 2022-08-02 |
| EP3607091A2 (en) | 2020-02-12 |
| KR20190137821A (ko) | 2019-12-11 |
| US20220340676A1 (en) | 2022-10-27 |
| JP2020512820A (ja) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019011986A (es) | Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas. | |
| CL2023000896A1 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
| CL2019001459A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1. | |
| CL2018002998A1 (es) | Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
| MX2019003886A (es) | Receptores de antigenos quimericos para el tratamiento del cancer. | |
| BR112022010206A2 (pt) | Receptores de antígeno quiméricos e usos dos mesmos | |
| CY1124153T1 (el) | Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127 | |
| MX2025010937A (es) | Constructos de anticuerpo biespecificos que se ligan a celulas t | |
| MX383216B (es) | Anticuerpos dirigidos contra la inmunoglobulina de células t y la proteína mucina 3 (tim-3). | |
| CO2020010277A2 (es) | Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl | |
| CO2021002954A2 (es) | Anticuerpos anti-αvβ8 y composiciones y usos de los mismos | |
| MX2023001791A (es) | Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r). | |
| CL2018000744A1 (es) | Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso. | |
| BR112018067458A2 (pt) | anticorpos para tigit | |
| CO2018000967A2 (es) | Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador | |
| MX366588B (es) | Cadena j modificada. | |
| CL2016002017A1 (es) | Inhibición dirigida del factor de crecimiento transformador b (tgfb). | |
| EA202192165A1 (ru) | Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы | |
| MX2017001011A (es) | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. | |
| UY36471A (es) | Anticuerpos contra el inmunorreceptor (tigit) de linfocitos t con dominios ig y motivos de inhibición del inmunorreceptor basados en tirosina (itim) | |
| MX387562B (es) | Anticuerpos y receptores de antigeno quimericos especificos para cd19. | |
| PE20160690A1 (es) | Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos | |
| MX380238B (es) | Anticuerpos especificos para mmp9. | |
| CL2017002596A1 (es) | Neutralización del virus chikungunya mediada por anticuerpos | |
| MX2016012273A (es) | Proteinas de union al antigeno vl que presentan diferentes caracteristicas de union. |